Momentum is building for Dogwood Therapeutics (DWTX) as its Phase 2b program moves toward a key interim analysis. With its lead candidate Halneuron advancing through a Phase 2b trial for chemotherapy-induced neuropathic pain (CINP), the next few quarters will be critical in shaping Dogwood's future.HALT-CINP Trial ProgressThe company recently announced enrollment of the first 100 patients in its o...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.